Literature DB >> 12954473

A population-based cohort study of mortality among adults prescribed paracetamol in Denmark.

Loren Lipworth1, Søren Friis, Lene Mellemkjaer, Lisa B Signorello, Søren P Johnsen, Gunnar L Nielsen, Joseph K McLaughlin, William J Blot, Jørgen H Olsen.   

Abstract

OBJECTIVE: We examined overall and cause-specific mortality in a population-based cohort of individuals prescribed paracetamol. We evaluated rates of death due to liver and renal disease, cancer, and other major causes of death.
METHOD: Using the population-based pharmacoepidemiology prescription database of North Jutland County, Denmark, we identified nearly 50,000 persons receiving prescriptions for paracetamol from 1989 to 1995 and evaluated mortality through 1996. Standardized mortality ratios (SMRs) for 18 specific causes of death were computed for persons prescribed paracetamol compared with persons among the general population of the county.
RESULTS: SMRs were elevated regardless of cause of death, with a nearly doubled overall death rate among persons prescribed paracetamol. The mortality ratios were highest within 1 year of paracetamol prescription and tended to decline with increasing follow-up, especially for cancers. The magnitudes of the excess mortality risks for liver and renal diseases were not materially higher than for other causes of death.
CONCLUSION: Paracetamol is a first-line analgesic for patients with a wide variety of chronic or serious illnesses and therefore is associated with increased rates of nearly all causes of death. The findings are an example of confounding by indication. Paracetamol may be a drug most prone to this form of bias in pharmacoepidemiologic studies. Future observational studies reporting adverse effects of paracetamol must thoroughly evaluate confounding by indication before making causal inferences.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954473     DOI: 10.1016/s0895-4356(03)00152-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  13 in total

1.  Paracetamol use and risk of ovarian cancer: a meta-analysis.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Nikolaos M Sitaras
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

2.  Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes.

Authors:  Frank de Vries; Efrosini Setakis; Tjeerd-Pieter van Staa
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

Review 3.  Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.

Authors:  P A Scott; G H Kingsley; C M Smith; E H Choy; D L Scott
Journal:  Ann Rheum Dis       Date:  2007-03-07       Impact factor: 19.103

4.  Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes.

Authors:  Ole Köhler; Liselotte Petersen; Ole Mors; Christiane Gasse
Journal:  Brain Behav       Date:  2015-05-29       Impact factor: 2.708

Review 5.  Paracetamol: not as safe as we thought? A systematic literature review of observational studies.

Authors:  Emmert Roberts; Vanessa Delgado Nunes; Sara Buckner; Susan Latchem; Margaret Constanti; Paul Miller; Michael Doherty; Weiya Zhang; Fraser Birrell; Mark Porcheret; Krysia Dziedzic; Ian Bernstein; Elspeth Wise; Philip G Conaghan
Journal:  Ann Rheum Dis       Date:  2015-03-02       Impact factor: 19.103

6.  Use of prescription paracetamol during pregnancy and risk of asthma in children: a population-based Danish cohort study.

Authors:  Ane Birgitte Telén Andersen; Dóra Körmendiné Farkas; Frank Mehnert; Vera Ehrenstein; Rune Erichsen
Journal:  Clin Epidemiol       Date:  2012-02-01       Impact factor: 4.790

7.  Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications.

Authors:  Rachel B Weinstein; Patrick Ryan; Jesse A Berlin; Amy Matcho; Martijn Schuemie; Joel Swerdel; Kayur Patel; Daniel Fife
Journal:  Drug Saf       Date:  2017-12       Impact factor: 5.606

Review 8.  Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?

Authors:  Philip G Conaghan; Nigel Arden; Bernard Avouac; Alberto Migliore; René Rizzoli
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

9.  Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen.

Authors:  Rachel B Weinstein; Patrick B Ryan; Jesse A Berlin; Martijn J Schuemie; Joel Swerdel; Daniel Fife
Journal:  Drug Saf       Date:  2020-09       Impact factor: 5.606

Review 10.  East meets West: current practices and policies in the management of musculoskeletal aging.

Authors:  Weibo Xia; Cyrus Cooper; Mei Li; Ling Xu; Rene Rizzoli; Mei Zhu; Hua Lin; John Beard; Yue Ding; Wei Yu; Etienne Cavalier; Zhenlin Zhang; John A Kanis; Qun Cheng; Quimei Wang; Jean-Yves Reginster
Journal:  Aging Clin Exp Res       Date:  2019-08-02       Impact factor: 3.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.